Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Synthetic peptide corresponding to residues 2-21 of mature human DR4.|
|Storage buffer||PBS with 0.05% BSA|
|Contains||0.05% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Western Blot (WB)||1-3 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Suggested positive control: Hela whole cell extract, HeLa cell lysate.
Cells undergo programmed cell death (Apoptosis) in response to various stimuli. Apoptosis is essential for morphogenesis, tissue homeostasis, and host defense (5). Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors, TNFR1 and Fas. A novel death domain containing receptor was recently identified and designated DR4 (for death receptor 4) (4). The ligand for this novel death receptor has been identified and termed TRAIL (2,3), which is a new member in the TNF family. DR4 is also called TRAIL receptor-1 (TRAIL-R1) (1). DR4 is expressed in most human tissues including spleen, peripheral blood leukocytes, small intestine and thymus. Like TNFR1, Fas and DR3, DR4 mediates apoptosis and NF-kB activation in many tissues and cells.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
APO2; CD261; cytotoxic TRAIL receptor; death receptor 4; DR4; MGC9365; TNF-related apoptosis-inducing ligand receptor 1; TRAIL receptor 1; TRAIL-R1; TRAILR-1; TRAILR1; tumor necrosis factor receptor superfamily member 10a variant 2; tumor necrosis factor receptor superfamily, member 10a
APO2; CD261; DR4; TNFRSF10A; TRAILR-1; TRAILR1